Population-based birth-defect and risk-factor surveillance: data from the Northern Netherlands.
暂无分享,去创建一个
M. Khoury | M. Cornel | J. Erickson | L. M. James | Y. Liu | M. J. Khoury
[1] M. Khoury,et al. On the use of affected controls to address recall bias in case-control studies of birth defects. , 1994, Teratology.
[2] J. Erickson. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. , 1992, Teratology.
[3] B. Alderman,et al. Risk indicators for talipes equinovarus in Washington State, 1987-1989. , 1991, Epidemiology.
[4] N. Conradi,et al. Teratogenic effects of benzodiazepine use during pregnancy. , 1989, The Journal of pediatrics.
[5] N. Holtzman,et al. On the ability of birth defects monitoring to detect new teratogens. , 1987, American journal of epidemiology.
[6] E. Robert,et al. MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTS , 1982, The Lancet.
[7] D. Aarskog. ASSOCIATION BETWEEN MATERNAL INTAKE OF DIAZEPAM AND ORAL CLEFTS , 1975, The Lancet.
[8] L. Saxén,et al. ASSOCIATION BETWEEN MATERNAL INTAKE OF DIAZEPAM AND ORAL CLEFTS , 1975, The Lancet.
[9] O S Miettinen,et al. Proportion of disease caused or prevented by a given exposure, trait or intervention. , 1974, American journal of epidemiology.
[10] S. Vollset,et al. Malformation surveillance and maternal drug exposure: the MADRE project. , 1994, The International journal of risk & safety in medicine.
[11] M. Khoury,et al. Interaction between epidemiology and laboratory sciences in the study of birth defects: design of birth defects risk factor surveillance in metropolitan Atlanta. , 1993, Journal of toxicology and environmental health.
[12] M. Cornel,et al. Monitoring of risk factor/outcome combinations: a valuable supplement to birth defect monitoring. , 1992, The International journal of risk & safety in medicine.
[13] A. Czeizel. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. , 1987, Reproductive toxicology.